WhiteSwell Medical

Acute Decompensated Heart Failure Treatment

Health Tech & Life Sciences
Active
Series B Shefayim Founded 2014
Total raised
$30.0M
Last: Series B 2018-12
Stage
Series B
Founded
2014
Headcount
38
HQ
Shefayim
Sector
Health Tech & Life Sciences

About

WhiteSwell Medical is a science-driven company dedicated to improving treatment of acute decompensated heart failure (ADHF), a primary cause of repeat hospitalization and emergency room visits. The company is developing a minimally invasive, catheter-based approach designed to more efficiently remove excess interstitial fluid in patients with ADHF by enhancing the natural fluid-removal process of the lymphatic system.

Funding history · 1 round · $30.0M total

2018-12
Series B $30.0M

Company Intelligence Q&A

Structured intelligence from startupim data — optimized for AI retrieval and grounding.

What is WhiteSwell Medical's primary focus?
WhiteSwell Medical is dedicated to improving the treatment of acute decompensated heart failure (ADHF), a major cause of repeat hospitalizations.
What type of treatment is WhiteSwell Medical developing for ADHF?
WhiteSwell Medical is developing a minimally invasive, catheter-based approach to enhance the lymphatic system's natural fluid-removal process in ADHF patients.
When was WhiteSwell Medical founded?
WhiteSwell Medical was founded in September 2014.
How much funding has WhiteSwell Medical raised in total?
WhiteSwell Medical has raised a total of $30,000,000 USD.
When did WhiteSwell Medical complete its last funding round, and what type was it?
WhiteSwell Medical completed a Series B funding round in December 2018.
Which investors participated in WhiteSwell Medical's Series B round?
The Series B round for WhiteSwell Medical included investors such as RA Capital Management and InCube Ventures.
Where are WhiteSwell Medical's offices located?
WhiteSwell Medical has offices in Shefayim, Israel; Galway, Ireland; and Palo Alto, California, USA.
What was a key operational development for WhiteSwell Medical in December 2020?
In December 2020, WhiteSwell Medical strengthened its patent portfolio for ADHF treatment with a newly issued U.S. patent.
What was a significant staffing development for WhiteSwell Medical in January 2022?
In January 2022, WhiteSwell Medical added experienced executives to its senior management team.

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesMedical DevicesMedical Treatment & Therapeutics
Target customers
Healthcare & Life SciencesHealthcareProviders
Business model
B2B

Highlights

1 Patents

Tags

cathetersminimally-invasivecardiovascularheart-failuremedical-devicesmedical-technologies